Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00430365 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Maintenance Therapy Using Lenalidomide in Myeloma

Study acronym: IFM2005-02
StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Publications: details revised at 1 of 2 entriesv18
  2. Trial status: Active, Not Recruiting to Completed
    • Study completion date changed from estimate of Sep 2020 to Sep 2018
    v17
  3. Study completion date: Sep 2017 to Sep 2020
    • Study sites revised (77)
    • Publications: details revised at 1 of 2 entries
    v16
  4. Primary and study completion dates: Sep 2016 to Sep 2017
    • Collaborators revised (2)
    v15
  5. Primary and study completion dates: Sep 2015 to Sep 2016v14
Show 12 earlier versionsHide 12 earlier versions
  1. Primary completion date: Feb 2015 to Sep 2015
    • Study completion date: Jun 2015 to Sep 2015
    v13
  2. Re-verified, no change to tracked fieldsv12
  3. Primary completion date: Feb 2012 to Feb 2015
    • Study completion date: Jun 2012 to Jun 2015
    • Eligibility criteria shortened, about 4 words
    v11
  4. Primary completion date: Feb 2011 to Feb 2012
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jun 2013 to Jun 2012
    • Site details revised at 77 of 77 sites
    v10
  5. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised at 77 of 77 sites
    v9
  6. Primary completion date: Jun 2009 to Feb 2011
    • Study sites: 2 to 77
    • Study completion date: Jun 2010 to Jun 2013
    v8
  7. Study Status, Conditions, Eligibilityv7
  8. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v6
  9. Re-verified, no change to tracked fieldsv5
  10. Primary completion date: Jun 2009
    • Study completion date: Jun 2009 to Jun 2010
    • Secondary endpoints revised (3)
    v4
  11. Re-verified, no change to tracked fieldsv3
  12. Interventions: Revlimid (Drug) to lenalidomide (Drug), placebo (Drug)
    • Study arms: 0 to 2
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Maintenance treatment of myeloma.
Trial Details
NCT Number NCT00430365
Lead Sponsor University Hospital, Toulouse
Collaborators: Intergroupe Francophone du Myelome, Celgene
Conditions
(from sponsor)		 Myeloma
Related terms Neoplasms, Plasma Cell
Enrollment 614 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov